دورية أكاديمية

Characterization of basal-like subtype in a Danish consecutive primary breast cancer cohort.

التفاصيل البيبلوغرافية
العنوان: Characterization of basal-like subtype in a Danish consecutive primary breast cancer cohort.
المؤلفون: Kinalis S; a Center for Genomic Medicine , Rigshospitalet, Copenhagen University Hospital , Copenhagen , Denmark., Nielsen FC; a Center for Genomic Medicine , Rigshospitalet, Copenhagen University Hospital , Copenhagen , Denmark., Talman ML; b Department of Pathology , Rigshospitalet, Copenhagen University Hospital , Copenhagen , Denmark., Ejlertsen B; c Denmark Danish Breast Cancer Cooperative Group , Rigshospitalet, Copenhagen University Hospital , Copenhagen , Denmark.; d Department of Clinical Oncology , Copenhagen University Hospital , Copenhagen , Denmark., Rossing M; a Center for Genomic Medicine , Rigshospitalet, Copenhagen University Hospital , Copenhagen , Denmark.
المصدر: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2018 Jan; Vol. 57 (1), pp. 51-57. Date of Electronic Publication: 2017 Nov 22.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8709065 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1651-226X (Electronic) Linking ISSN: 0284186X NLM ISO Abbreviation: Acta Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: London : Informa Healthcare
Original Publication: Stockholm, Sweden : Acta Oncologica, [1987-
مواضيع طبية MeSH: Breast Neoplasms/*genetics , Breast Neoplasms/*pathology , Triple Negative Breast Neoplasms/*genetics , Triple Negative Breast Neoplasms/*pathology, Age Factors ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Breast Neoplasms/metabolism ; Cohort Studies ; Denmark ; Female ; Hedgehog Proteins/metabolism ; Heterozygote ; Humans ; Middle Aged ; Mutation ; Proto-Oncogene Proteins p21(ras)/metabolism ; Transcriptome ; Triple Negative Breast Neoplasms/metabolism ; Up-Regulation ; Wnt Signaling Pathway
مستخلص: Background: Transcriptome analysis enables classification of breast tumors into molecular subtypes. BRCA1/2 predisposed patients are more likely to suffer from a basal-like subtype and this group of patients displays a more distinct phenotype and genotype. Hence, in-depth characterization of this separate entity is needed.
Material and Methods: Molecular subtyping was performed on a consecutive and unselected series of 1560 tumors from patients with primary breast cancer. Tumors were classified by the 256 gene expression signature (CIT) and associated with basic clinical characteristics and aggregated expression levels in the hallmark gene sets.
Results: Of the 1560 samples, 168 were classified basal-like and 120 patients were screened for BRCA1/2 mutations, resulting in 19 BRCA1/2 carriers, 95 non-carriers and six patients carried variants of unknown significance. The BRCA1/2 carriers were significantly younger and there were no carriers above 60 years of age. The tumors showed a loss in DNA-repair profile, as well as an upregulation in proliferative cancer signaling pathways. A robust molecular signature for identification of the BRCA1/2 - carriers was infeasible in the current cohort. Patients with a basal like breast cancer had the lowest median age and the largest median tumor size. They were almost exclusively diagnosed in disease stage III.
Conclusions: Basal-like subtype is indeed a separate entity compared with other molecular breast cancer subtypes and the clinical course for this patient group should reflect the aggressiveness of this cancer. Taken together, patients being diagnosed with a basal-like breast cancer are in the youngest segment of breast cancer patients and are mainly diagnosed in stage III disease.
المشرفين على المادة: 0 (BRCA1 Protein)
0 (BRCA1 protein, human)
0 (BRCA2 Protein)
0 (BRCA2 protein, human)
0 (Hedgehog Proteins)
0 (KRAS protein, human)
EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
تواريخ الأحداث: Date Created: 20171123 Date Completed: 20180201 Latest Revision: 20180201
رمز التحديث: 20231215
DOI: 10.1080/0284186X.2017.1398837
PMID: 29164968
قاعدة البيانات: MEDLINE
الوصف
تدمد:1651-226X
DOI:10.1080/0284186X.2017.1398837